___

• 1. Anonymous, 2006. The Use of Mushroom Preparations in Malignancies. Thomas Jefferson University Hospital , July 2006.
• 2. Anonymous, 2009. Food and Agriculture Organization of the United Nations (FAO), (http://faostat.fao.org).
• 3. Benedict, R.G. and L.R. Brady, 1972. Antimicrobial Activity of Mushroom Metabolites. Jour. of Pharmaceutical Sciences 61 (11), 1820- 182.
• 4. Carlile, M.J. and S. C. Watkinson, 1994. The Fungi. Academic Press London, pp.373-409.
• 5. Chang, S. T. and J. A. Buswell, 1996. Mushroom Nutriceuticals. World J. Microbiol Biotechnol 12, 473-476.
• 6. Chang, S. T., 1999. World Production of Cultivated Edible and Medicinal Mushrooms in 1997 With Emphasis on Lentinus edodes (Berk.) Sing. in China. International J. Med. Mush. 1: 291–300.
• 7. Conchran, K.W., 1978. Medicinal Effects, in: The Biology and Cultivition of Edible Musrooms (Ed. Chung, S.T. and Hayes, W.A.), Academic Press, New York.
• 8. Denis, R. B., 1995. Mushrooms : Poisons and Panaceas, W.H. Freeman and Co, New York.
• 9. Fujimiya, Y., Y. Suzuki, K. Oshiman, H. Kobori, K. Moriguchi, H. Nakashima, Y. Matumoto, S. Takahara, T. Ebina and R. Katakura, 1998. Selective Tumoricidal Effect of Soluble Proteoglucan Extracted From the Basidiomycete, Agaricus blazei Murill, Mediated Via Natural Killer Cell Activation and Apoptosis. Cancer Immunol Immunother, 46:147-159.
• 10. Hajjaj, H., C. Macé, M. Roberts, P. Niederberger and LB. Fay, 2005. Effect of 26-Oxygenosterols from Ganoderma lucidum and Their Activity as Cholesterol Synthesis Inhibitors. Appl. Environ. Microbiol.;71(7):3653-8.
• 11. Karmali, A., 2008. SOD Activity, Cytochrome P-450, Cytochrome P-450 Reductase and Secondary Metabolites - Chemical and Biological Properties in Mushroom Nutrition. International Mycotherapy Institute. Page 9-11
• 12. Lakhanbal, T.N. and M. Rana 2005. Medicinal and Nutraceutical Genetic Resources of Mushrooms. Cambridge University Pres, Plant Genetic Resources, 3, pp 288-303.
• 13. Liu, Y. K. and W. Shen, 2003. Inhibitive Effect of Cordyceps sinensis on Experimental Hepatic Fibrosis and its Possible Mechanism. World J. Gastroenterol 9 (3):529-533.
• 14. Mayell, M., 2001. Maitake Extracts and Their Therapeutic Potential – A Review. Alternative Medicine Review - Volume 6, Number 1:48-60.
• 15. Mizuno, T., 1999. The Extraction and Development of Antitumor – Active Polysaccharides from Medical Mushrooms in Japan (Review). International Journal of Medical Mushrooms, (1) 1: 9-29.
• 16. Nanba, H. and K. Kubo, 1997. Effect of Maitake D-Fraction on Cancer Prevention. Ann N Y Acad Sci., 1997; 833: 204- 207.
• 17. Okuda, K. L., 2007. Nature’s Powerful Immune Support from the Brazilian Rainforests. Nutrition Professional’s Journal Volume 7:14-17.
• 18. Sarıkürkçü, C., S.D Karslı, M.H. Solak ve M. Harmandar, 2004. MuğlaYöresi Yenilebilir Mantar Ekstraktlarının Antioksidant Aktivitelerinin Belirlenmesi. Türkiye 8. Gıda Kongresi. 26- 28 Mayıs 2004. Bursa. s. 57.
• 19. Wasser, S.P. and A.L. Weis, 1999. Medical Properties of Substances Occurring in Higher Basidiomycetes Mushrooms: Current Perspectives (Review). International Journal of Medical Mushrooms, (1)1: 31- 62.
• 20. Yamaguchi, Y., S. Kagota, K. Nakamura, K. Shinozuka and M. Kunitomo, 2000. Antioxidant Activity of the Extracts from Fruiting Bodies of Cultured Cordyceps sinensis. Phytotherapy Research. Volume: 14;8: 647-649.
• 21. Yamamura, Y. and K.W., Cochran, 1974a. Chronic hypocholesterolemic Effect of Lentinus edodes in Mice and Absence of Effect on Scrapie. Mushroom Sci., 9: 489- 493.
• 22. Yamamura, Y., Cochran, K.W., 1974b. A selective inhibitor of myxoviruses from shiitake (L. edodes). Mushroom Sci., 9: 495- 507.
• 23. Zhang, H., F. Gong, Y. Feng and C. Zhang, 1999. Flammulin Purified from the Fruit Bodies of Flammulina velutipes (Curt .:Fr.) P. Karst. International Journal of Medical Mushrooms, (1)1: 89- 92. .